Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

By sjmartinez • July 5, 2024

Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Jul 2:S0016-5085(24)05181-3. doi: 10.1053/j.gastro.2024.06.028. Epub ahead of print. PMID: 38964420.

Tags: AAT, alpha-1 antitrypsin deficiency, Fazirsiran, Liver disease, Publications, Pulmonary, Critical Care & Sleep Medicine, Z-AAT

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Rebuilding the foundation: recommendations from the Summit to Revitalize Primary Care (Rev PC)

Summit to Revitalize Primary Care Writing Committee*; Jerant A, Kravitz RL, Fenton JJ, Lyles CR, Grumbach K, Henderson MC, Ritley D, Brandt M, Cohen D,[...]

Hepatocyte growth factor may contribute to male protection against pulmonary arterial hypertension

Medzikovic L, Ruffenach G, Dehghanitafti A, Wong B, Ryder A, Hatamnejad MR, Sun W, Esdin L, Eghbali J, Brownstein A, Razee A, Umar S, Hong[...]